A number of studies have also reported metabolic pathway changes in the aneurysmal wall compared with the normal arterial wall; for example, BAF60a deficiency in vascular smooth muscle cells can prevent the occurrence and progression of AAA by reducing inflammation and extracellular matrix degradation [38]. The gene discussed is SMARCD1; the disease is triple-A syndrome.